Latest News and Press Releases

Independent Data Safety Monitoring Board declared dose level 2 as safe and recommended escalation to final dose level 3 Munich, Germany – December 4, 2024 – Thermosome, a drug development company...

-    Experienced biopharma professional focused on drug product development Munich, Germany - June 11, 2024 - Thermosome, a drug development company focused on targeted tumor therapies, today...

MONMOUTH JUNCTION, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy, announced today that Geno...

-    First dose level rated as safe by independent Data Safety Monitoring Board-    Second dose level to be administered according to plan-    THE001 designed as targeted tumor treatment independent...

-    Two renowned oncology experts to support the development of Thermosome's clinical candidate THE001 Munich, Germany – December 05, 2023 – Thermosome, a drug development company specializing...

Leveraging the transformative potential of TSL-based tumor targeting Supporting the progress of Thermosome's clinical candidate THE001 Munich, Germany – September 19, 2023 – Thermosome, a drug...

MONMOUTH JUNCTION, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy, announced today an...

MONMOUTH JUNCTION, N.J., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy, announced today that...

New York, USA, Nov. 10, 2022 (GLOBE NEWSWIRE) -- The Worldwide Cancer Monoclonal Antibodies Market size in 2021 was USD 51.88 billion and will be worth USD 108.47 billion with an 8.54% CAGR. A...